首页> 外文期刊>Human psychopharmacology: clinical and experimental >Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach.
【24h】

Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach.

机译:抗精神病药物和2型糖尿病的风险:以证据为基础的方法。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To review studies conducted to evaluate the risk of type 2 diabetes in patients treated with different antipsychotic drugs (AP). METHODS: a MEDLINE search (January 1985-February 2003) was conducted to establish the potential relationship between the exposure to AP (conventional and second generation) and the development of type 2 diabetes. Studies were classified according to their experimental design as prospective and retrospective (incidence and prevalence based). RESULTS: Twenty-one studies were selected: nine prospective and eleven retrospective. DATA SYNTHESIS AND CONCLUSIONS: Patients with schizophrenia treated with different AP have an increased risk of developing type 2 diabetes compared with the general population. The data so far available, however, do not establish whether the increasing risk of developing diabetes is a function of the schizophrenia itself or is induced by the antipsychotic treatment. A number of methodological flaws in the study design and data collection do notallow conclusions to be drawn on the risk between patients treated with conventional drugs versus those treated with new ones.
机译:目的:评估研究进行了评估2型糖尿病患者治疗的风险不同抗精神病药物(美联社)。MEDLINE搜索(1985年1月- 2003年2月)进行建立潜在的关系在暴露于美联社(常规和之间第二代)和2型的发展糖尿病他们的实验设计和前瞻性回顾(基于发病率和患病率)。结果:21个研究选择:9前瞻性和11个回顾。合成和结论:患者精神分裂症治疗AP有不同增加患2型糖尿病的风险与普通人群相比。然而,目前可用的不确定增加患糖尿病的风险精神分裂症本身或者是的函数诱导的抗精神病药物治疗。研究设计和方法论上的缺陷数据收集做notallow结论画在患者之间的风险常规药物和治疗的人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号